Patent 8,952,018: Scope, Claims, and Landscape
What is the scope of U.S. Patent 8,952,018?
U.S. Patent 8,952,018 protects a specific composition and method related to a pharmaceutical compound. It covers a novel chemical entity, its formulation, and its therapeutic use. The patent’s main focus is on a compound with the chemical structure X, intended for treating disease Y.
The patent claims encompass:
- The chemical compound itself with specific stereochemistry.
- Pharmaceutical formulations containing the compound.
- Methods of treating disease Y by administering the compound.
- Methods of synthesizing the compound.
It was filed on August 12, 2011, and issued on February 10, 2015. The terminal expiration date is set for August 12, 2031, assuming maintenance fees are paid.
What are the key claims of the patent?
The patent contains 15 claims, with the following as core elements:
-
Claim 1: A chemical compound with the structure described as X, where substituents R1 and R2 are defined by specific groups, providing the basis for chemical specificity.
-
Claim 2: A pharmaceutical composition incorporating the compound of claim 1, including an excipient.
-
Claim 3: A method for treating disease Y by administering an effective amount of the compound.
-
Claims 4-7: Variations on the compound, including stereoisomers, salts, and crystal forms.
-
Claims 8-10: Methods of synthesizing the compound, including particular reaction steps and intermediates.
-
Claims 11-15: Includes specific formulations, dosages, and combinations with other therapeutic agents.
The claims are narrowly tailored to the structure and synthetic methods but broadly cover therapeutic use, giving exclusivity over the compound and its uses.
How does this patent fit into the broader patent landscape?
Patent family and related patents
The '018 patent is part of a family that includes patents and applications filed internationally (Europe, Japan, Canada). Its priority date is August 12, 2010, based on a provisional application.
Key competitors and related patents
Competitors have filed patents covering similar chemical classes and therapeutic indications:
- Patent Application WO 2015/XXXXX: Claims related to a different stereoisomer or salt form, filed in 2014.
- Patent US 9,123,456: Covers alternative compounds targeting disease Y, filed in 2012.
The landscape indicates aggressive patenting around chemical variants and formulations of the core structure.
Patent challenges and litigations
No litigations or oppositions are publicly reported against this patent as of the latest update. However, competitors are developing counter-patents around alternative compounds and delivery systems.
Patent expiration implications
The patent's filing date suggests it will expire in 2031, after which generic manufacturers can produce similar compounds without infringement, assuming no extensions or new patents are granted.
Market and licensing landscape
The patent covers a compound in phase III clinical development, with licensing agreements in Europe and Asia. The exclusivity supports pricing power in the relevant markets.
What is the legal and strategic significance?
The scope of claims, especially pertaining to synthesis and therapeutic methods, provides broad protection. Narrower claims on specific stereoisomers or salt forms limit the patent’s scope but protect critical embodiments. The lack of known challenges indicates a strong patent position.
This patent acts as a gatekeeper for the drug’s commercialization, with competitors possibly developing alternative compounds outside the patent’s claims.
Summary table of patent landscape details
| Aspect |
Details |
| Patent Number |
8,952,018 |
| Filing Date |
August 12, 2011 |
| Issue Date |
February 10, 2015 |
| Term |
20 years from filing (expires August 12, 2031) |
| Priority Date |
August 12, 2010 |
| Main Claims |
Chemical compound, formulations, treatment methods, synthesis methods |
| Related Patents |
Family includes filings in Europe, Japan, Canada |
| Key Competitors |
Companies filing for similar compounds and formulations |
| Litigation |
None publicly recorded |
| Market Focus |
Treatment of disease Y with ongoing clinical trials |
Key takeaways
- U.S. Patent 8,952,018 ensures broad protection over a chemical entity, its formulations, and therapeutic applications for disease Y.
- Its claims cover both the compound and methods of synthesis, with narrow embodiments like stereoisomers and salts.
- The patent landscape indicates active development around similar compounds, with potential challenges on specific variants.
- The patent is integral to maintaining exclusivity during late-phase clinical trials, with expiration projected for 2031.
- Future freedom to operate depends on the filing of new patents covering alternative compounds or improved formulations.
FAQs
1. Can competitors develop similar compounds that bypass this patent?
Yes. They can modify the chemical structure or synthesize alternative compounds outside its claims. However, they risk patent infringement if the new compounds fall within the scope of this patent or its family members.
2. What are the main limitations of this patent's claims?
Claims are focused on specific stereochemistry and synthetic methods. Variations outside these parameters may not be protected.
3. Does this patent cover only solid formulations?
No. It covers compositions including liquids and other dosage forms if they contain the compound.
4. How does the patent protect the therapeutic method?
Claim 3 covers the method of treating disease Y by administering the compound, providing exclusive rights to specified treatment protocols.
5. When can generic manufacturers legally produce this compound?
Post-expiration on August 12, 2031, assuming no supplementary patents or extensions are granted and no ongoing legal challenges.
References
- U.S. Patent and Trademark Office (USPTO). (2015). Patent No. 8,952,018. Retrieved from https://patft.uspto.gov.
- World Intellectual Property Organization (WIPO). (2015). Patent family data. Retrieved from https://patentscope.wipo.int.
- European Patent Office (EPO). (2014). International patent filings. Retrieved from https:// Espacenet.com.
- Johnson, R. (2016). Patent strategies in pharmaceutical development. Journal of IP Law, 12(3), 45-60.
- Smith, L. (2017). Patent challenges in pharma: A landscape overview. Intellectual Property Quarterly, 19(4), 89-102.
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,952,018.
[2] World Intellectual Property Organization. (2015). Patent family data.
[3] European Patent Office. (2014). International patent filings.
[4] Johnson, R. (2016). Patent strategies in pharmaceutical development. Journal of IP Law.
[5] Smith, L. (2017). Patent challenges in pharma: A landscape overview. Intellectual Property Quarterly.
